A pioneering biotechnology company focusing on rare disease therapeutics is exploring innovative methods for delivering drugs to cardiac tissues to treat genetic cardiomyopathy. Solutions should address the following: enhanced site-specific targeting, improved biodistribution profile, sustained and controlled release, and de-risked safety and immunogenicity. Approaches enabling the delivery of antisense oligonucleotides, micro-RNAs, small-interfering RNAs and small-activating RNAs are of the highest priority.
Submission of 200–300-word briefs is encouraged, along with any supplementary information e.g. relevant publications, patents or slide decks. The team encourages including the proposed next steps in developing the research towards commercialization. In submitting to this campaign, you confirm that your submission contains only non-confidential information.
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include funded research collaborations and agreements or licencing of assets.
Technology
Academic Researcher
Centre of Excellence
Research Project
Spinout Company
Biotech Asset
Technology
Academic Researcher
Centre of Excellence
Research Project
Spinout Company
Biotech Asset
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.